Coreline Soft said that it has confirmed the efficacy of AVIEW CAC, an artificial intelligence (AI)-based heart disease diagnosis solution, and published the results in an international journal.
"The study, conducted by the Institute for Diagnostic Accuracy (iDNA), which consists of the NELSON team, the largest lung cancer screening clinical trial team in Europe, is the first case in the world that verified the competitiveness and stability of an AI heart disease diagnosis solution compared to an experienced interpreter," the company said.
The iDNA research team performed a retrospective study using data from the Robinsca screening trial and investigated the effectiveness of each diagnosis in screening and clinical settings using AVIEW CAC.
"Through the trial, the team recommended AVIEW CAC in the screening environment as showed similar performance to that of a cardiologist specializing in cardiovascular disease," the company said. "However, in the clinical setting, the team revealed that the performance was somewhat uncertain in the very low: 0-9.9 range with a low CAC value."
As a result, the research team confirmed the diagnostic accuracy of the AI solution was 99.2 percent and said that AVIEW CAC showed the best results among low-dose computed tomographies.
"This study confirmed the possibility of more efficient diagnosis by independently reading and classifying data by AI in the diagnosis of cardiovascular disease," Nelson lead researcher, Professor Matthijis Oudkerk, said. "In the future, the team expects AI will be a powerful means of increasing the survival rate of patients by helping radiologists and early detection of cardiovascular diseases."
Coreline Soft CEO Kim Jin-kook also said, "As heart disease is the second-leading cause of death worldwide, early diagnosis is very important for diagnosis and treatment."
Therefore, it is meaningful that the company received recognition for its technology and accuracy of the company's AI diagnostic solution based on real data, he added.
Kim stressed that the study results created a tool for early diagnosis of coronary artery abnormalities and will help create an opportunity to expand cardiac health in developed countries.
The results of the study were published in the Journal of the American College of Cardiology.